関節リウマチ治療の市場規模、シェア、動向分析レポート：分子別、販売チャネル別、地域別、セグメント予測、2024年～2030年

関節リウマチ治療市場の成長と動向：

Grand View Research, Inc.の最新調査によると、世界の関節リウマチ治療市場規模は2030年までに363億9,000万米ドルに達し、2024～2030年のCAGRは5.93%で拡大すると予測されています。

予測期間中のCAGRは4.6%で拡大します。市場を牽引する主要動向としては、新規生物製剤の入手可能性、潜在的臨床パイプライン候補の増加、高齢化人口の増加などが挙げられます。このように、より安全な薬剤の入手可能性と認知度の高まりが、関節リウマチ治療市場の成長をエスカレートさせると予測されています。

関節リウマチは世界人口の約1％が罹患しています。この疾患には、関節の痛み、腫れ、こわばりといったさまざまな症状があり、一般的に慢性的な痛みを伴い、日常的な活動ができなくなります。この疾患は長期にわたると、患者の運動能力を妨げ、関節の永久的な損傷につながる可能性があります。未治療のまま放置すると、この疾患は運動機能障害や人工関節置換術のリスクにつながる可能性があります。

この疾患の有病率の増加、生物製剤とバイオシミラーの存在、明確に定義された規制ガイドラインは、市場に弾みをつける構えです。Arthritis Foundationによると、米国では65歳以下の人口の64％が関節炎に罹患している可能性があります。疾患送金療法に関する意識の高まりと先進地域における医療費の増加は、収益の成長を促進すると推定されます。

関節リウマチの現在の治療には、JAK阻害剤やIL-6拮抗剤などの新規生物製剤に加え、非ステロイド性抗炎症薬（NSAIDs）や副腎皮質ステロイドなどのジェネリック医薬品があり、その高い有効性から先進国で広く使用されています。インフリキシマブやアダリムマブのバイオシミラーのような新製品の上市は、市場に有利に働くと予想されます。さらに、Eli LillyのOlumiantとAbbVieのUpadacitinibは、疾患の再発の可能性を減らすと期待されています。

関節リウマチ治療市場レポートハイライト

• バイオ医薬品セグメントが市場をリードし、2023年の世界売上高の88.73%を占める。バイオ医薬品は、生物学的資源から製造、抽出、合成される高分子医薬品です。
• 2023年の市場シェアは89.64%で、処方薬が市場をリードしています。リウマチ専門医による診察が増加するにつれ、処方薬セグメントが予測期間中、関節リウマチ治療市場で優位を保つと予想されます。
• 北米の関節リウマチ治療市場は、2023年に52.31%のシェアを占めました。この地域市場は、人口動態の変化、医療研究の進歩、規制の変更、個別化医療の重視の高まりなどを背景に、成長と進化を続けています。
• アジア太平洋の関節リウマチ治療市場は、関節リウマチの有病率の増加、医療インフラの改善、治療オプションの進歩に牽引され、大きな成長を遂げています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブ概要

第3章 関節リウマチ治療市場の変数、動向、範囲

• 関節リウマチ治療市場の系統展望
  • 親市場の展望
  • 補助市場の展望-変形性関節症治療市場
• 市場力学
  • 市場ドライバー分析
  • 市場抑制要因分析
• 関節リウマチ治療市場分析ツール
  • ポーターのファイブフォース分析
  • PESTLE分析

第4章 関節リウマチ治療市場分析、分子別、2018～2030年（100万米ドル）

• 関節リウマチ治療：分子変動分析
• 関節リウマチ治療市場分析：分子別
  • バイオ医薬品
  • 医薬品

第5章 関節リウマチ治療市場分析、販売チャネル別、2018～2030年（100万米ドル）

• 関節リウマチ治療：販売チャネル変動分析
• 関節リウマチ治療市場分析：販売チャネル別
  • 処方薬
  • 市販薬（OTC）

第6章 関節リウマチ治療市場：分子別、販売チャネル別の地域推定・動向分析

• 関節リウマチ治療市場：地域別展望
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 市場参入企業の分類
• 主要企業プロファイル
  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • UCB SA
  • Johnson &Johnson Services, Inc.
  • AG Amgen, Inc.
  • Lilly（Eli Lilly and Company）

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. Global rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 4. Global rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 5. North America rheumatoid arthritis therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 6. North America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 7. North America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 8. U.S. rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 9. U.S. rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 10. Canada rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 11. Canada rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 12. Mexico rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 13. Mexico rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 14. Europe rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
• Table 15. Europe rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 16. Europe rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 17. UK rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 18. UK rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 19. Germany rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 20. Germany rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 21. France rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 22. France rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 23. Italy rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 24. Italy rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 25. Spain rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 26. Spain rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 27. Norway rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 28. Norway rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 29. Sweden rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 30. Sweden rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 31. Denmark rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 32. Denmark rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 33. Asia Pacific rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
• Table 34. Asia Pacific rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 35. Asia Pacific rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 36. Japan rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 37. Japan rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 38. China rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 39. China rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 40. India rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 41. India rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 42. Australia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 43. Australia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 44. South Korea rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 45. South Korea rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 46. Thailand rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 47. Thailand rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 48. Latin America rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
• Table 49. Latin America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 50. Latin America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 51. Brazil rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 52. Brazil rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 53. Argentina rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 54. Argentina rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 55. Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
• Table 56. Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 57. Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 58. South Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 59. South Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 60. Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 61. Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 62. UAE rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 63. UAE rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
• Table 64. Kuwait rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
• Table 65. Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Rheumatoid arthritis therapeutics market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Molecule and sales channel segment snapshot
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Global Pharmaceutical Market, (USD billion)
• Fig. 13 Market dynamics
• Fig. 14 Porter's five forces analysis
• Fig. 15 PESTLE analysis
• Fig. 16 Rheumatoid arthritis therapeutics: Molecule outlook and key takeaways
• Fig. 17 Rheumatoid arthritis therapeutics market: Molecule market movement analysis
• Fig. 18 Biopharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 T-cell inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 JAK inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Anti-IL6 biologics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 DMARDs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Glucocorticoids market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
• Fig. 34 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
• Fig. 35 Prescription market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Over-the-Counter (OTC) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Rheumatoid arthritis therapeutics market revenue, by region, 2023 & 2030 (USD Million)
• Fig. 38 Regional marketplace: Key takeaways
• Fig. 39 Regional marketplace: Key takeaways
• Fig. 40 North America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Key country dynamics
• Fig. 42 U.S. rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 U.S. healthcare system: money flow
• Fig. 44 Key country dynamics
• Fig. 45 Canada rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Drug pricing
• Fig. 47 Key country dynamics
• Fig. 48 Mexico rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Regulatory framework
• Fig. 50 Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Key country dynamics
• Fig. 52 UK rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Key country dynamics
• Fig. 54 Germany rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Key country dynamics
• Fig. 56 France rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 Spain rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Key country dynamics
• Fig. 60 Italy rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Key country dynamics
• Fig. 62 Denmark rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Key country dynamics
• Fig. 64 Sweden rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Key country dynamics
• Fig. 66 Norway rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Rest of Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 Japan rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Key country dynamics
• Fig. 72 China rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 China regulatory details
• Fig. 74 India rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 Australia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 Thailand rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 South Korea rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 South Korea reimbursement scenario
• Fig. 82 Rest of Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Key country dynamics
• Fig. 85 Brazil rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Brazil regulation details
• Fig. 87 Brazil reimbursement scenario
• Fig. 88 Key country dynamics
• Fig. 89 Argentina rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Argentina regulatory framework
• Fig. 91 Rest of Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Key country dynamics
• Fig. 93 South Africa rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Key country dynamics
• Fig. 95 Saudi Arabia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 96 Key country dynamics
• Fig. 97 UAE rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Key country dynamics
• Fig. 99 Kuwait rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2023 (USD Million)
• Fig. 100 Rest of MEA rheumatoid arthritis therapeutics market estimates and forecasts,
• Fig. 101 Company/competition categorization
• Fig. 102 Company market share analysis, 2023
• Fig. 103 Strategy mapping

Rheumatoid Arthritis Therapeutics Market Growth & Trends:

The global rheumatoid arthritis therapeutics market size is expected to reach USD 36.39 billion by 2030, expanding at a CAGR of 5.93% from 2024 to 2030, according to a new study by Grand View Research, Inc. expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth.

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly's Olumiant and AbbVie's Upadacitinib are expected to cut down chances of disease remittance.

Rheumatoid Arthritis Therapeutics Market Report Highlights:

• Biopharmaceuticals segment led the market and accounted for 88.73% of the global revenue in 2023. Biopharmaceuticals are large-molecule drugs that are manufactured, extracted, and synthesized from biological sources.
• Prescription led the market with a market share of 89.64% in 2023. As rheumatologist consultations rise, the prescription segment is expected to remain dominant in the market for rheumatoid arthritis medications over the forecast period.
• North America rheumatoid arthritis therapeutics market accounted for 52.31% share in 2023. The regional market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare.
• The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and advancements in treatment options.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule
  • 1.2.2. Sales channel
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Molecule and Sales Channel Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, and Scope

• 3.1. Rheumatoid Arthritis Therapeutics Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary market outlook - Osteoarthritis Therapeutics Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of rheumatoid arthritis
    • 3.2.1.2. Launch of novel therapeutic agents
    • 3.2.1.3. Shift in treatment from the relief of symptoms to targeted therapy
    • 3.2.1.4. Favorable reimbursement policies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of rheumatoid arthritis therapeutic drugs
    • 3.2.2.2. Side effects and adverse reactions
• 3.3. Rheumatoid Arthritis Therapeutics Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTLE Analysis

Chapter 4. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule, 2018 - 2030 (USD Million)

• 4.1. Rheumatoid Arthritis Therapeutics: Molecule Movement Analysis
• 4.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule Market (USD Million)
  • 4.2.1. Biopharmaceuticals
    • 4.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2. Biologics
    • 4.2.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.2. TNF-a antagonists
    • 4.2.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.3. T-cell inhibitors
    • 4.2.1.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.4. CD20 antigen
    • 4.2.1.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.5. JAK inhibitors
    • 4.2.1.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.6. anti-IL6 biologics
    • 4.2.1.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.3. Biosimilars
    • 4.2.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.3.2. CD20 antigen
    • 4.2.1.3.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.3.4. TNF-a antagonists
    • 4.2.1.3.5. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.2.2. Pharmaceuticals
    • 4.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2.2. NSAIDs
    • 4.2.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2.3. Analgesics
    • 4.2.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2.4. DMARDs
    • 4.2.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2.5. Glucocorticoids
    • 4.2.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel, 2018 - 2030 (USD Million)

• 5.1. Rheumatoid Arthritis Therapeutics: Sales Channel Movement Analysis
• 5.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel Market (USD Million)
  • 5.2.1. Prescription
    • 5.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.2.2. Over-the-Counter (OTC)
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates and Trend Analysis by Molecule, by Sales Channel

• 6.1. Rheumatoid Arthritis Therapeutics Market: Regional Outlook
• 6.2. North America
  • 6.2.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2. U.S.
    • 6.2.2.1. Key Country Dynamics
    • 6.2.2.2. Target Disease Prevalence
    • 6.2.2.3. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2.4. Competitive/Market Scenario
    • 6.2.2.5. Regulatory Framework
    • 6.2.2.6. Reimbursement scenario
  • 6.2.3. Canada
    • 6.2.3.1. Key Country Dynamics
    • 6.2.3.2. Target Disease Prevalence
    • 6.2.3.3. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3.4. Competitive/Market Scenario
    • 6.2.3.5. Regulatory Framework
    • 6.2.3.6. Reimbursement Scenario
  • 6.2.4. Mexico
    • 6.2.4.1. Key Country Dynamics
    • 6.2.4.2. Target Disease Prevalence
    • 6.2.4.3. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4.4. Competitive/Market Scenario
    • 6.2.4.5. Regulatory Framework
    • 6.2.4.6. Reimbursement Scenario
• 6.3. Europe
  • 6.3.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. UK
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Target Disease Prevalence
    • 6.3.2.3. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2.4. Competitive/Market Scenario
    • 6.3.2.5. Regulatory Framework
    • 6.3.2.6. Reimbursement Scenario
  • 6.3.3. Germany
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3.4. Competitive/Market Scenario
    • 6.3.3.5. Regulatory Framework
    • 6.3.3.6. Reimbursement Scenario
  • 6.3.4. France
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Target Disease Prevalence
    • 6.3.4.3. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4.4. Competitive/Market Scenario
    • 6.3.4.5. Regulatory Framework
    • 6.3.4.6. Reimbursement Scenario
  • 6.3.5. Spain
    • 6.3.5.1. Key Country Dynamics
    • 6.3.5.2. Target Disease Prevalence
    • 6.3.5.3. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5.4. Competitive/Market Scenario
    • 6.3.5.5. Regulatory Framework
    • 6.3.5.6. Reimbursement Scenario
  • 6.3.6. Italy
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Target Disease Prevalence
    • 6.3.6.3. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6.4. Competitive/Market Scenario
    • 6.3.6.5. Regulatory Framework
    • 6.3.6.6. Reimbursement Scenario
  • 6.3.7. Denmark
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Target Disease Prevalence
    • 6.3.7.3. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7.4. Competitive/Market Scenario
    • 6.3.7.5. Regulatory Framework
    • 6.3.7.6. Reimbursement Scenario
  • 6.3.8. Sweden
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Target Disease Prevalence
    • 6.3.8.3. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8.4. Competitive/Market Scenario
    • 6.3.8.5. Regulatory Framework
    • 6.3.8.6. Reimbursement Scenario
  • 6.3.9. 6.3.9 Norway
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Target Disease Prevalence
    • 6.3.9.3. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9.4. Competitive/Market Scenario
    • 6.3.9.5. Regulatory Framework
    • 6.3.9.6. Reimbursement Scenario
    • 6.3.9.7. Rest of Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Japan
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2.4. Competitive/Market Scenario
    • 6.4.2.5. Regulatory Framework
    • 6.4.2.6. Reimbursement Scenario
  • 6.4.3. China
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3.4. Competitive/Market Scenario
    • 6.4.3.5. Regulatory Framework
    • 6.4.3.6. Reimbursement Scenario
  • 6.4.4. India
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4.4. Competitive/Market Scenario
    • 6.4.4.5. Regulatory Framework
    • 6.4.4.6. Reimbursement Scenario
  • 6.4.5. Australia
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5.4. Competitive/Market Scenario
    • 6.4.5.5. Regulatory Framework
    • 6.4.5.6. Reimbursement Scenario
  • 6.4.6. Thailand
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6.4. Competitive/Market Scenario
    • 6.4.6.5. Regulatory Framework
    • 6.4.6.6. Reimbursement Scenario
  • 6.4.7. South Korea
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7.4. Competitive/Market Scenario
    • 6.4.7.5. Regulatory Framework
    • 6.4.7.6. Reimbursement Scenario
    • 6.4.7.7. Rest of Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2.4. Competitive/Market Scenario
    • 6.5.2.5. Regulatory Framework
    • 6.5.2.6. Reimbursement Scenario
  • 6.5.3. Argentina
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3.4. Competitive/Market Scenario
    • 6.5.3.5. Regulatory Framework
    • 6.5.3.6. Reimbursement Scenario
    • 6.5.3.7. Rest of Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. MEA
  • 6.6.1. MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2.4. Competitive/Market Scenario
    • 6.6.2.5. Regulatory Framework
    • 6.6.2.6. Reimbursement Scenario
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3.4. Competitive/Market Scenario
    • 6.6.3.5. Regulatory Framework
    • 6.6.3.6. Reimbursement Scenario
  • 6.6.4. UAE
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4.4. Competitive/Market Scenario
    • 6.6.4.5. Regulatory Framework
    • 6.6.4.6. Reimbursement Scenario
  • 6.6.5. Kuwait
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5.4. Competitive/Market Scenario
    • 6.6.5.5. Regulatory Framework
    • 6.6.5.6. Reimbursement Scenario
  • 6.6.6. Rest of MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. AbbVie, Inc.
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Boehringer Ingelheim International GmbH
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Novartis AG
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Regeneron Pharmaceuticals Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Pfizer, Inc.
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Bristol-Myers Squibb Company
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. F. Hoffmann-La Roche Ltd.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. UCB S.A.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Johnson & Johnson Services, Inc.
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. AG Amgen, Inc.
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Lilly (Eli Lilly and Company)
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives